Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 7
2004 12
2005 11
2006 12
2007 20
2008 20
2009 40
2010 44
2011 41
2012 63
2013 75
2014 73
2015 91
2016 114
2017 123
2018 156
2019 190
2020 240
2021 250
2022 350
2023 354
2024 462
2025 523
2026 125

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,018 results

Results by year

Filters applied: . Clear all
Page 1
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.
Qu WF, Zhu GQ, Yang R, Chu TH, Guan ZQ, Huang R, Tian MX, Jiang XF, Tao CY, Fang Y, Gao J, Wu XL, Chen JF, Zhao QF, Wang Y, Bu YC, Zhou J, Fan J, Liu WR, Tang Z, Shi YH. Qu WF, et al. Among authors: yang r. Sci Adv. 2025 May 2;11(18):eads8597. doi: 10.1126/sciadv.ads8597. Epub 2025 May 2. Sci Adv. 2025. PMID: 40315321 Free PMC article.
Human LY9 governs CD4+ T cell IFN-γ immunity to Mycobacterium tuberculosis.
Ogishi M, Puchan J, Yang R, Arias AA, Han JE, Nguyen T, Gutiérrez-Cózar R, Conil C, Seeleuthner Y, Rinchai D, Zhang P, Ponsin K, Chaldebas M, Feng Y, Neehus AL, Delmonte OM, Khan T, Landegren N, Eriksson D, Bohlen J, Peel JN, Fagniez I, Pelham SJ, Lei WT, Chrabieh M, Laine C, Ouair H, Benhsaien I, Abid A, Abderrhamani Ghorfi I, Souhi H, Ouazzani H, Aniss R, Riminton DS, Kämpe O, Turvey SE, Marr N, Notarangelo LD, Hatipoglu N, Bousfiha A, Ozcelik T, El Baghdadi J, Cobat A, Ma CS, Abel L, Puel A, Bustamante J, Engel P, Gros P, Tangye SG, Sallusto F, Boisson-Dupuis S, Casanova JL. Ogishi M, et al. Among authors: yang r. Sci Immunol. 2025 May 30;10(107):eads7377. doi: 10.1126/sciimmunol.ads7377. Epub 2025 May 30. Sci Immunol. 2025. PMID: 40446017 Free PMC article.
Disruption of TAD hierarchy promotes LTR co-option in cancer.
Wong EWP, Sahin M, Yang R, Lee U, Li D, Zhan YA, Misra R, Tomas F, Alomran N, Polyzos A, Lee CJ, Trieu T, Martinez-Fundichely A, Wiesner T, Rosowicz A, Cheng S, Liu C, Lallo M, Shoushtari AN, Merghoub T, Hamard PJ, Koche R, Khurana E, Apostolou E, Zheng D, Chen Y, Leslie CS, Chi P. Wong EWP, et al. Among authors: yang r. Nat Genet. 2025 Jul;57(7):1754-1765. doi: 10.1038/s41588-025-02239-6. Epub 2025 Jun 30. Nat Genet. 2025. PMID: 40588507 Free PMC article.
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial.
Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M, Duan F, Sheth RA, Rao P, Sircar K, Shah AY, Zurita AJ, Genovese G, Li M, Yeh CC, Dang M, Han G, Chu Y, Hallin M, Olson P, Yang R, Slavin D, Der-Torossian H, Chin CD, Tannir NM, Wang L, Gao J. Msaouel P, et al. Among authors: yang r. Nat Commun. 2025 Jan 10;16(1):578. doi: 10.1038/s41467-024-55642-8. Nat Commun. 2025. PMID: 39794332 Free PMC article. Clinical Trial.
3,018 results